Original language | English (US) |
---|---|
Pages (from-to) | 2252-2256 |
Number of pages | 5 |
Journal | Blood |
Volume | 139 |
Issue number | 14 |
DOIs | |
State | Published - Apr 7 2022 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. / Purroy, Noelia; Tong, Yuzhou Evelyn; Lemvigh, Camilla K.; Cieri, Nicoletta; Li, Shuqiang; Parry, Erin M.; Zhang, Wandi; Rassenti, Laura Z.; Kipps, Thomas J.; Slager, Susan L.; Kay, Neil Elliot; Lesnick, Connie; Shanafelt, Tait D; Ghia, Paolo; Scarfò, Lydia; Livak, Kenneth J.; Kharchenko, Peter V.; Neuberg, Donna S.; Olsen, Lars Rønn; Fan, Jean; Gohil, Satyen H.; Wu, Catherine J.
In: Blood, Vol. 139, No. 14, 07.04.2022, p. 2252-2256.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
AU - Purroy, Noelia
AU - Tong, Yuzhou Evelyn
AU - Lemvigh, Camilla K.
AU - Cieri, Nicoletta
AU - Li, Shuqiang
AU - Parry, Erin M.
AU - Zhang, Wandi
AU - Rassenti, Laura Z.
AU - Kipps, Thomas J.
AU - Slager, Susan L.
AU - Kay, Neil Elliot
AU - Lesnick, Connie
AU - Shanafelt, Tait D
AU - Ghia, Paolo
AU - Scarfò, Lydia
AU - Livak, Kenneth J.
AU - Kharchenko, Peter V.
AU - Neuberg, Donna S.
AU - Olsen, Lars Rønn
AU - Fan, Jean
AU - Gohil, Satyen H.
AU - Wu, Catherine J.
N1 - Funding Information: This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: The authors thank Jerome Ritz and the DFCI Pasquarello Tissue Bank in Hematologic Malignancies for prospective collection and processing of blood samples from healthy donors. This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: Conflict-of-interest disclosure: N.P. is currently an employee of AstraZeneca; C.J.W. holds equity in BioNTech, Inc. and receives research funding from Pharmacyclics. S.H.G. has received speaker fees from Janssen UK and travel and honoraria from AbbVie and provides research consultancy for Novalgen Limited. P.G. has received honoraria from AbbVie, AstraZeneca, ArQule MSD, BeiGene, Celgene/Juno/BMS, Janssen, Loxo/Lilly, and Roche and research funding from AbbVie, AstraZeneca, Janssen, and Sunesis. P.V.K serves on the scientific advisory boards of Celsius Therapeutics Inc. and Biomage Inc. N.E.K. serves on the advisory boards of AbbVie, Astra Zeneca, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology and on the data safety monitoring committees of Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, and Rigel and research funding from AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. L.S. has received honoraria from AbbVie, AstraZeneca, Janssen and travel funding from Janssen. T.D.S. received institutional research support from Genentech and Phamacyclics. The remaining authors declare no competing financial interests.
PY - 2022/4/7
Y1 - 2022/4/7
UR - http://www.scopus.com/inward/record.url?scp=85127488881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127488881&partnerID=8YFLogxK
U2 - 10.1182/blood.2021013926
DO - 10.1182/blood.2021013926
M3 - Letter
C2 - 35020831
AN - SCOPUS:85127488881
VL - 139
SP - 2252
EP - 2256
JO - Blood
JF - Blood
SN - 0006-4971
IS - 14
ER -